Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Olmetyle 40 AH Tablet is a fixed-dose combination of Olmesartan Medoxomil 40mg, Amlodipine 5mg, and Hydrochlorothiazide 12.5mg, formulated to effectively manage hypertension in patients requiring multi-drug therapy. Olmesartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by relaxing blood vessels. Amlodipine, a calcium channel blocker, enhances vasodilation and improves blood flow, while Hydrochlorothiazide is a thiazide diuretic that helps eliminate excess sodium and water, reducing overall blood volume. This triple combination offers a synergistic approach for patients with moderate to severe hypertension, ensuring better blood pressure control and reducing the risk of cardiovascular complications.
Common side effects may include dizziness, headache, fatigue, swelling of ankles (due to amlodipine), increased urination, and electrolyte imbalance. Rare but serious side effects can include hypotension, kidney dysfunction, or allergic reactions. If any unusual symptoms occur, consult a physician immediately.
Olmetyle 40 AH Tablet is indicated for the management of essential hypertension, especially in patients who require a combination of an ARB, calcium channel blocker, and diuretic to achieve optimal blood pressure control. It may be prescribed when monotherapy or dual therapy is insufficient.
Use only as directed by a healthcare professional. Regular monitoring of blood pressure, kidney function, and electrolytes is essential during treatment. Not recommended during pregnancy. Patients should avoid abrupt discontinuation and should be advised to stay hydrated, especially in hot weather.
Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Metoprolol Succinate 100mg PR Tablet
Composition : Metoprolol Succinate 50mg + Ramipril 5mg Tablet
Composition : Metoprolol Succinate 25mg + Ramipril 2.5mg Tablet
Composition : Losartan 25mg Tablet
Composition : Losartan 50mg Tablet
Composition : Losartan 50mg + Hydrochlorothiazide 12.5mg Tablet
Composition : Losartan 50mg + Chlorthalidone 6.25mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan Medoxomil 40 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg Tablet is a high-strength triple-combination antihypertensive medication used for the management of moderate to severe or resistant hypertension (high blood pressure). It combines Olmesartan Medoxomil (ARB), Amlodipine (calcium channel blocker), and Hydrochlorothiazide (diuretic), providing a multi-mechanism approach for effective and sustained blood pressure control. This makes it a premium product in the cardiology and cardiovascular care segment, with strong demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from high-value prescriptions from cardiologists and specialty physicians. Triple therapy is commonly used in resistant and uncontrolled hypertension cases, ensuring strong prescription demand, repeat orders, and long-term market stability, making it a premium addition to any cardiovascular portfolio.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong institutional demand, high prescription value, long-term patient adherence, and increasing use of combination therapy in hypertension management, making this product a high-margin and sustainable addition to their pharmaceutical business when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in advanced cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.